ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer
ImPact Biotech, a biotechnology company in its clinical stage dedicated to advancing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy for various solid tumors, announced on December 20, 2023, that the U.S. Food and Drug Administration (FDA) has granted clearance for the Company's Investigational New Drug (IND) application that allows the commencement of a Phase 1 study targeting patients with unresectable pancreatic adenocarcinoma (PDAC).
Padeliporfin VTP (Vascular Targeted Photodynamic) therapy represents a minimally invasive approach in oncology for addr...
